Home > Healthcare > Medical Devices > Diagnostic Devices > Anthrax Vaccine Market

Anthrax Vaccine Market Share

Report ID: GMI9546
Published Date: May 2024
Report Format: PDF

Download Free Sample

Anthrax Vaccine Market Share

The anthrax vaccine industry is characterized by the presence of several key players focusing on research, development, and commercialization of anthrax vaccines. Companies such as Emergent BioSolutions, Bavarian Nordic, and Elusys Therapeutics are among the prominent players in this market. These companies are actively engaged in developing innovative vaccines and enhancing their production capacities to meet the increasing demand for anthrax vaccines. Additionally, collaborations, partnerships, and acquisitions are common strategies adopted by these players to strengthen their market presence. The market is also witnessing the entry of new players, which is intensifying the competition and driving innovation in the development of anthrax vaccines.

Anthrax Vaccine Market Companies

Prominent players operating in the anthrax vaccine industry include:

Altimmune Inc.
Agrovet
Bayer AG
Bavarian Nordic
Biogenesis Bago SA
Ceva Sante Animale
Colondo Serum Company
Emergent BioSolutions
Elusys Therapeutics Inc.
Indian Immunologicals Ltd.
Intervac (PVT) Ltd
JOVAC
Merck Co, Inc.
Proton Biopharma Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for anthrax vaccine was worth USD 11.9 billion in 2023 and is projected to expand at 5.4% CAGR from 2024 to 2032, due to the increasing awareness about anthrax as a potential bioterrorism threat.

The cell free PA vaccine segment in the anthrax vaccine industry reached USD 6.7 billion in 2023 and is projected to expand at substantial rate from 2024 to 2032, owing to the improved safety profiles compared to whole-cell vaccines.

The veterinary use segment in the anthrax vaccine industry held 81.8% share in 2023 and is estimated to witness robust growth between 2024 and 2032, due to the rising need to prevent the spread of anthrax in animal populations, protecting both animals and humans from the disease.

North America industry recorded USD 4.7 billion in revenue in 2023 and is estimated to depict significant growth between 2024 to 2032, on account of the growing awareness among livestock animal caretakers regarding their immunization against anthrax.